Study finds GLP-1 drugs can help curb SUDs
A study published by BMJ found that glucagon-like peptide-1 (GLP-1) drugs could help reduce the risk of various substance use disorders, including for alcohol, cannabis, nicotine, cocaine and opioids. The study examined records of more than 600,000 patients from the Department of Veterans Affairs who had Type 2 diabetes and took a GLP-1 or a sodium-glucose cotransporter-2 inhibitor, or SGLT2, for treatment. Additionally, the study found that people with pre-existing SUDs who took GLP-1 drugs had reduced risks of SUD-related emergency room visits, hospital admissions, overdose, suicide and death.
Related News Articles
Headline
In this conversation, a team from the University Medical Center New Orleans — LSU School of Medicine’s Benjamin Springgate, M.D., professor of …
Headline
Heidi Bray, DNP, nurse practitioner and hospitalist at Providence St. Peter Hospital, explores how hospitals can improve opioid use disorder treatment through…
Headline
The AHA will host a webinar June 16 at 1 p.m. ET that will share insights from its Bridge to Care Toolkit, designed to help hospitals and health systems…
Headline
The Drug Enforcement Administration today released a final rule implementing provisions from the Restoring Hope for Mental Health and Well-Being Act of 2022,…
Headline
The AHA has won two Telly Awards for its three-part video series, Voices of Leadership: Breaking Mental Health Stigma. The Telly Awards, a global…
Headline
In this conversation, three leaders from CommonSpirit Health explore how the organization is confronting stigma about substance use head-on through education,…